News & Events

Other Events. Investment Agreement with MiRus LLC On May 18, 2026, Boston Scientific Corporation (the “ Company ”) issued a press release announcing that the Company has entered into an investment agreement (the “ Investment Agreement ”) with MiRus LLC (“ MiRus ”), a privately held company developing and commercializing proprietary novel biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the Siegel transcatheter aortic valve…

Other Events. Accelerated Share Repurchase Program On May 18, 2026, Boston Scientific Corporation (the “ Company ”) issued a press release announcing that the Company has entered into an accelerated share repurchase (“ ASR ”) agreement with JPMorgan Chase Bank, National Association for $2 billion (the “ Repurchase Price ”) of its common stock, as part of its previously announced $5 billion share repurchase authorization. Under the terms of the ASR, the Company will pay the repurchase price an…

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. With respect to the 2026 Credit Agreements, the information set forth above under

Entry into a Material Definitive Agreement. Revolving Credit Agreement On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. The Company may borrow from time to time up to $3,000,000,000 in revolving credit loans under the 2026 Revolving C…

Termination of a Material Definitive Agreement. In connection with the entry into the 2026 Revolving Credit Agreement, on February 26, 2026, the Company terminated a prior revolving credit agreement, dated as of May 10, 2021, as amended by that certain Amendment to the Credit Agreement dated as of December 21, 2022, the Second Amendment to the Credit Agreement, dated as of March 1, 2023, and the Third Amendment to the Credit Agreement, dated as of May 10, 2024, by and among the Company, as bo…

Other Events. On February 18, 2026, the Board approved an increase to the Company’s existing authorization to repurchase up to $1.0 billion of the Company’s common stock, par value $0.01 per share (“ Common Stock ”), by an additional $4.0 billion. As a result, the Company is authorized to repurchase up to a total of $5.0 billion of Common Stock under the Company’s stock repurchase program, all of which remains available as of the date hereof.

Director — Catherine R. Smith, Christophe P. Weber: Two new directors were appointed to the Board.

Director — Yoshiaki Fujimori: Mr. Fujimori will not stand for re-election at the Company’s 2026 Annual Meeting.

of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Director — John E. Sununu: Mr. Sununu will not stand for re-election at the 2026 Annual Meeting.

Executive Vice President and President, Peripheral Interventions — Jeffrey B. Mirviss: Mr. Mirviss is retiring from his role but will remain as a senior advisor.

Other Events. On May 28, 2025, Boston Scientific Corporation (the “Company”) announced it is discontinuing worldwide sales of the ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems and no longer pursuing U.S. FDA approval for ACURATE or approval in other geographies. The Company made this decision based on recent discussions with regulators, which resulted in increased clinical and regulatory requirements to maintain regulatory approvals in global markets and to obtain approvals in new reg…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 9, 2025, Charles J. Dockendorff informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”). Mr. Dockendorff has served as a member of the Board of Directors (the “Board”) of the Company since April 2015 and currently serve…

OTHER EVENTS As previously disclosed, on January 8, 2024, Boston Scientific Corporation, a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Sadie Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub ”), and Axonics, Inc., a Delaware corporation (“ Axonics ”), providing for the merger of Merger Sub with and into Axonics (the “ Merger ”), with Axonics surviving the Merger as a wholly…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On January 26, 2024, the Board of Directors (the “Board”) of Boston Scientific Corporation (the “Company”) appointed Jonathan Monson as Senior Vice President, Investor Relations, effective March 1, 2024. Mr. Monson currently serves as Senior Vice President, Global Controller and Chief Accounting Officer, a position he has held since July 2019; e…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 29, 2023, Donna A. James informed the Company that she will not stand for re-election at the Company’s 2023 Annual Meeting. Ms. James has served as a member of the Board of Directors (Board) since July 2015 and currently serves as the chair of the Executive Compensation and Human Resources Committee and a member of the Nominating and Gov…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On March 30, 2022, David A. Pierce, executive vice president and president, MedSurg and president, Endoscopy, informed Boston Scientific Corporation (“Boston Scientific” or the “Company”), that he will retire, effective July 4, 2022. Mr. Pierce joined the Company in 1991 and has served in a number of roles of increasing responsibility. During t…

OTHER EVENTS . On November 8, 2021, Boston Scientific Corporation (the “Company”) completed its acquisition of Devoro Medical Inc. (“Devoro Medical”), a privately-held company which developed the WOLF Thrombectomy® Platform, a non-console and lytic-free platform designed to rapidly capture and extract blood clots in arterial, venous and pulmonary embolism procedures. The Company had been a strategic investor in Devoro Medical since 2019 and held an equity stake of approximately 16 percent pri…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Election of Directors On June 24, 2021, Boston Scientific Corporation (the “Company”) filed a Current Report on Form 8-K announcing the appointment of David S. Wichmann to the Company’s Board of Directors (the “Board”) on June 23, 2021. At the time of filing of that report, the Board had not determined the committee assignments for Mr. Wichmann…